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Abstract
Background: Cyclin-dependent protein kinase-5 (CDK5) is an unusual member of the CDK family as it is not cell cycle
regulated. However many of its substrates have roles in cell growth and oncogenesis, raising the possibility that CDK5
modulation could have therapeutic benefit. In order to establish whether changes in CDK5 activity are associated with
oncogenesis one could quantify phosphorylation of CDK5 targets in disease tissue in comparison to appropriate
controls. However the identity of physiological and pathophysiological CDK5 substrates remains the subject of
debate, making the choice of CDK5 activity biomarkers difficult.
Methods: Here we use in vitro and in cell phosphorylation assays to identify novel features of CDK5 target sequence
determinants that confer enhanced CDK5 selectivity, providing means to select substrate biomarkers of CDK5 activity
with more confidence. We then characterize tools for the best CDK5 substrate we identified to monitor its
phosphorylation in human tissue and use these to interrogate human tumour arrays.
Results: The close proximity of Arg/Lys amino acids and a proline two residues N-terminal to the phosphorylated
residue both improve recognition of the substrate by CDK5. In contrast the presence of a proline two residues C-terminal
to the target residue dramatically reduces phosphorylation rate. Serine-522 of Collapsin Response Mediator-2 (CRMP2) is a
validated CDK5 substrate with many of these structural criteria. We generate and characterise phosphospecific antibodies
to Ser522 and show that phosphorylation appears in human tumours (lung, breast, and lymphoma) in stark contrast to
surrounding non-neoplastic tissue. In lung cancer the anti-phospho-Ser522 signal is positive in squamous cell carcinoma
more frequently than adenocarcinoma. Finally we demonstrate that it is a specific and unusual splice variant of CRMP2
(CRMP2A) that is phosphorylated in tumour cells.
Conclusions: For the first time this data associates altered CDK5 substrate phosphorylation with oncogenesis in some
but not all tumour types, implicating altered CDK5 activity in aspects of pathogenesis. These data identify a novel
oncogenic mechanism where CDK5 activation induces CRMP2A phosphorylation in the nuclei of tumour cells.
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Background
CDK5 is a Serine/Threonine. protein kinase belonging to
the CMGC subfamily. CDK5 is the catalytic subunit of an
active heterodimeric complex consisting of CDK5 bound
to either p35 or p39, two similar CDK5 cofactors encoded
for by different genes (CDK5R1 and CDK5R2) [1, 2]. These
regulatory subunits have little primary sequence homology
to cyclins but possess domains with three-dimensional
structures similar to the Cdk-binding motif of cyclins [3, 4]
and are highly selective in their binding of CDK5 [5]. The
levels of p35 and p39 are not regulated through the cell
cycle suggesting the function of CDK5 is not related to that
of its cyclin binding relatives that are crucial regulators of
cell cycle progression.
Mice lacking CDK5 die just before or after birth, with
serious defects in neuronal layering of many brain struc-
tures [6–8]. p35 null mice have a similar inverted cortical
layering observed in the CDK5 null mouse but are viable
with normal cerebellum, suggesting variable redundancy in
p35 and p39 protein function across the brain [9–11]. The
p35 null mice exhibit increased susceptibility to seizures,
while the p39 null mice have little apparent deficit, which
may suggest that p35 is the more dominant regulator of
CDK5 activity. Meanwhile, mice lacking both p35 and p39
have a very similar phenotype to that of the CDK5 null
mouse providing evidence that p35 or p39 regulation of
CDK5 is required for development of the brain [12].
As such, CDK5 has predominantly been studied in post-
mitotic neurons, the major site of expression of p39 and
p35. The main mode of CDK5 regulation in neurons is
currently thought to be modulation of the expression or
stability of p35 and p39. The proteolytic clipping of these
proteins by the calcium regulated protease calpain pro-
duces p25 and p29, respectively [13, 14]. This alters the
subcellular localization of the p25/p29 proteins, and the
associated CDK5 catalytic subunit, since the N-terminal
portion of p35/p39 that is lost contains a membrane
localization domain. p25 is reported to be more stable
than p35, and p25/CDK5 complexes are reported to con-
tain intrinsically higher activity [15], which would have
obvious implications on CDK5 substrate phosphorylation
in diseases with altered p35-p25 ratio. However the rele-
vance of p35 to p25 ratio on steady state CDK5 substrate
phosphorylation, and subsequent disease development re-
mains to be fully appreciated.
There is a diverse array of proposed substrates of CDK5,
although most have not been validated as true physiological
substrates in vivo or even in intact cells. Most substrates of
CDK5 identified to date have key neuronal functions.
These include tau [16, 17], and CRMP2 [18–20], with
hyperphosphorylation of these proteins being associated
with the generation of neurofibrillary tangles, one of the
two hallmarks of Alzheimer’s disease. The phosphorylation
of Pctaire 1, spinophilin, axin and neurabin 1 by CDK5
regulates the development of dendritic spines and axons
[21–23] while NMDA receptor activity is increased
through the phosphorylation of its NR2A subunit by
CDK5 [24], and dopaminergic signalling is controlled by
CDK5 through the phosphorylation of dopamine cAMP-
regulated phosphoprotein of 32 kDa, DARPP32 [25]. This
substrate profile reflects the neuronal focus of CDK5 re-
search and, combined with the lack of cell cycle regulation
of its activity, means that CDK5 has generally not been as-
sociated with a key role in cancer initiation, progression or
therapy. However, more ubiquitous cell regulatory actions
of CDK5 outside of the brain are well described [26, 27].
In addition there are many lines of evidence linking
CDK5 to growth and cancer related actions. These
include; i) the phosphorylation of oncogenic proteins
such as Rb [28], ATM [29], Bcl-2 [30], p53 [31], STAT3
[32], and talin [33], ii) the observed dysregulation of
CDK5 activity in leukaemia [34] and pancreatic carcin-
oma cells [35, 36], iii) a significant correlation between
the expression of p35/CDK5 and the degree of differen-
tiation and metastasis in non-small cell lung cancer
[37], as well as increased expression and activity of
CDK5 in human hepatocellular carcinoma (HCC) [38],
iv) an association between polymorphisms in the CDK5
promoter and lung cancer risk in a specific Korean
population [39], v) the demonstration that CDK5 acti-
vation enhances medullary thyroid carcinoma (MTC) in
a conditional mouse model [40, 41], while inhibition of
CDK5 activity reduces tumour growth, motility and
metastasis in pancreatic cancer cells [35] [42, 43], and
ablation/inhibition of CDK5 significantly decreased
HCC cell proliferation [38].
All of the above data suggests abnormal activation of
CDK5 increases the risk of, or aggressiveness of, spe-
cific forms of cancer. However there are also reports
that pharmacological (roscovitine) or siRNA inhibition
of CDK5 enhances the proliferation of the breast can-
cer cell lines MCF-7 and MDA-MB321, while applica-
tion of carboplatin, a chemotherapeutic used in the
treatment of breast cancer, induces CDK5 activation
[44]. Similarly, CDK5 levels decrease in gastric cancer
and its nuclear accumulation suppresses gastric tumori-
genesis [45].
Although this indicates a complex relationship be-
tween CDK5 activity and growth of different cancer
types, the general theme is that tight regulation of
CDK5 activity is important for normal cell physiology
and that localised or temporal gain (or loss) of function
is associated with abnormal cell proliferation. This com-
plex relationship makes it vital to develop the means to
accurately assess CDK5 activity in tissue to clarify the
potential contribution that this kinase plays in tumouri-
genesis and whether it presents any novel opportunities
for intervention.
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The aims of our study were to identify high-confidence
substrates as biomarkers of CDK5 activity in tissue and
use these surrogate marker(s) of CDK5 activity to establish
whether CDK5 activity was altered in human carcinoma.
Methods
Materials
Peptides (Additional file 1: Table S1) were synthesized by
Pepceuticals Ltd, Enderby, Leicestershire UK. Active forms
of the CMGC protein kinases were purchased from MRC
Protein Phosphorylation Reagents, University of Dundee,
except for p35/CDK5 and p25/CDK5 (Millipore UK Ltd,
Herts, UK).
Antibodies: The pCRMP2 Ser522 and pCRMP4 Ser522
were generated in-house as previously described [20] and
are available from MRC Protein Phosphorylation Reagents,
University of Dundee (mrcppureagents.dundee.ac.uk), while
the pTau S202 (Cell Signalling, catalog. No.11834), pTau
T205 (Invitrogen, catalog. No.44-738G), and pTau S235
(Bioworld, catalog. No.BS4193) antibodies were commer-
cially available.
DNA Constructs: The generation of the expression con-
structs for human CRMP proteins have been described pre-
viously [20], while human tau expression constructs were
obtained from MRC Protein Phosphorylation Reagents,
University of Dundee. Expression constructs for CDK5,
p35 and p25 were generated by Dr Margereta Nikolic,
Imperial College, London.
Cell culture
Embryonic primary cortical neurons were isolated from
Sprague–Dawley rats at day 18 gestation. Briefly, follow-
ing dissection, cortex was digested in 0.25 % trypsin in
Hank’s balanced salt solution at 37 °C for 20 min. Cells
were manually dissociated by trituration using a fire-
polished Pasteur pipette and plated onto 0.01 % poly-l-
lysine-coated coverslips at a density of 2–5 × 106 cells
per 6 cm well, then incubated at 37 °C with 5 % CO2 in
Neurobasal medium (Gibco) containing 2 % (vol/vol)
B27 serum replacement (Invitrogen), penicillin (Sigma;
100 units/ml), streptomycin (Sigma; 100 μg/ml), and
1 % (vol/vol) L-glutamine (Sigma). HeLa and tumour
cell lines were maintained in DMEM supplemented
with 4.5 g/L glucose, 10 % (vol/vol) FCS, 1 % (vol/vol)
penicillin (100 units/ml)/streptomycin (100 μg/ml) at
37 °C in 5 % CO2.
Plasmids were introduced into cells using Lipofectamine
2000 (Invitrogen) as per manufacturers instructions. Cells
were incubated for 4 h at 37 °C before the transfection
medium was removed and replaced with 5 ml growth
medium. Cells were then incubated overnight at 37 °C,
prior to lysis or fixation as below.
Cell lysis for protein isolation
Cells were lysed in ice-cold lysis buffer (1 % (v/v) Triton
X-100, 50 mm Tris–HCl, pH 7.5, 0.27 M sucrose, 1 mM
EDTA, 0.1 mM EGTA, 1 mM sodium orthovanadate,
50 mM sodium fluoride, 5 mM sodium pyrophosphate,
0.1 % (vol/vol) β-mercaptoethanol, and Complete prote-
ase inhibitor tablet (1 per 10 ml, Roche Applied Science,
Basel, Switzerland)). Following centrifugation to remove
insoluble material, supernatants were collected, and
protein concentrations determined using the Bradford
method.
Immunofluorescence
Neurons were fixed in 4 % (w/v) paraformaldehyde in
PBS for 10 min at 4 °C, permeabilised with 0.1 % (v/v)
Triton X-100 in TBS for 3 min at room temperature,
blocked with 1 % (w/v) BSA in TBS containing 0.005 %
(v/v) Tween-20 for 1 h at room temperature, and incu-
bated with primary antibodies diluted 1:50 in PBS con-
taining 5 % (w/v) BSA for 1 h at room temperature.
Secondary antibodies conjugated to Cy-3 fluorophores
were diluted 1:250 in PBS containing 5 % (w/v) BSA and
incubated with neurons for 1 h at room temperature.
Neurons were counterstained with 0.5 ug/mL DAPI so-
lution (Invitrogen). Image acquisition was performed on
a Leica SP-5 laser scanning confocal imaging system
using 63× objectives.
Immunohistochemistry
Ethical approval was obtained by review through the Tissue
Access Committee of Tayside Tissue Bank (approval #
TR338) and the studies follow the Guidelines of the
Declaration of Helsinki for the use of human tissues for
research. Sections of formalin-fixed, paraffin embedded
tissue were cut at a thickness of 4 μm, collected onto
Polysine-coated microscope slides (VWR International)
and dried overnight at 37 °C. Sections were dewaxed in
Histoclear, rinsed in alcohol and endogenous peroxid-
ase was quenched with 0.5 % hydrogen peroxide (100
volumes) in methanol at room temperature for 35 min.
After washing in water, antigen retrieval was performed
by boiling sections in 10 mM citrate buffer, pH 6.0 for
15 min in a microwave. After cooling, sections were
rinsed in PBS and blocked with 5 % normal serum in
PBS containing 5 % (v/v) avidin (Vector Laboratories,
Peterborough, UK) for 30 min at room temperature.
Sections were washed in PBS and incubated with pri-
mary antibody in 5 % normal serum in PBS containing
5 % (v/v) biotin at 4 °C overnight. After washing in
PBS, sections were then incubated with biotinylated
secondary antibody (1:250) (Vector Laboratories) for
30 min at room temperature, followed by streptavidin
complexed with biotinylated peroxidase (Vectastain
ABC kit; Vector Laboratories) at room temperature for
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30 min. The peroxidase complexes were visualized
using 0.25 mg/ml diaminobenzidine tetrahydrochloride
(DAB) (Sigma) in PBS containing 5 mM imidazole
(pH 7.0) and 0.075 % hydrogen peroxide for 10 min at
room temperature. Cell nuclei were counterstained
with haematoxylin (Sigma), dehydrated through graded
alcohols, cleared in HistoClear and mounted in DPX.
Images were taken using a Spot Insight QE digital cam-
era or slides were digitally scanned (x40) using an
Aperio ScanScope XT.
Cell fractionation
Adherent cells (1–10 × 106 cells) were harvested in
0.05 % (w/v) trypsin-EDTA and pelleted at 500× g for
5 min, washed 2x in PBS before subcellular fractionation
which was preformed to the manufacturer’s specifica-
tions (Thermo Scientific- Cell fractionation Kit).
Assay of purified protein kinase activity
Specific activity (pmol/min) was determined for all pro-
tein kinases by incubating known amounts of kinase
(0.01-1 μg) with the generic substrate myelin basic pro-
tein (MBP, 0.3 mg/ml final) in kinase buffer (25 mM
MOPS pH 7.5, 0.05 % (v/v) Brij-35, 0.25 mM EDTA, 5 %
(v/v) glycerol) plus 10 mM MgCl2, and 100 μM [γ-32P]
ATP (approx 0.5 × 106 CPM/nmol) as previously de-
scribed [46]. Peptide kinase assays were performed with
2mUnits of each kinase as above, except MBP was re-
placed with the peptide at the concentration given in fig-
ure legends. One unit of activity of each protein kinase
was calculated as 1 nmole of phosphate transferred/min.
Phosphorylation of protein substrates
Recombinant protein substrates were incubated with
2mUnits of each CMGC kinase as for MBP above for
the times and at the concentrations given in figure leg-
ends. Reactions were terminated by the addition of SDS-
PAGE loading buffer and heating to 70 °C for 15 mins.
Aliquots were subjected to SDS-PAGE, stained with
Coomassie Brilliant Blue (CBR-250), the gels were dried
and radiolabeled bands visualized by autoradiography.
Quantification of nmoles of phosphate incorporated was
obtained by excising the stained protein band from the
gel and counting in scintillation fluid.
Western blotting
SDS loading buffer was added to cell lysates and samples
subjected to electrophoresis on 4-15 % polyacrylamide
gels (Invitrogen) prior to transfer to nitrocellulose using
the XCell II blot module (Invitrogen). Blots were
blocked in 5 % (w/v) milk in TBST (50 mM Tris HCl
pH7.4, 150 mM NaCl, and 0.1 % (v/v) Tween-20) and
incubated overnight at 4 °C with the primary antibody
diluted in 5 % (w/v) milk in TBST. Blots were washed in
TBST and bound antibodies were detected using sec-
ondary antibodies linked to a fluorescent conjugate dye.
Blots were visualized using a LICOR Odyssey® Infrared
Imaging System (LICOR, Lincoln, NE).
Mass Spectroscopy
GST-tau (0.5 μM) was incubated with either p25/CDK5 or
p35/CDK5 and MgATP for 5, 20 or 60 mins. Reactions
were stopped by addition of 4× SDS-PAGE sample buffer
prior to alkylation. GST-tau was isolated by SDS-PAGE,
identified by coomassie staining and the destained protein
band digested with 0.1 ml 2 g/ml trypsin in 50 mM TEAB
overnight. Digests were extracted with 0.1 ml acetonitrile,
supernatants dried, dissolved in 0.1 ml 5 % acetonitrile/
0.25 % FA and 15 μl of sample from each time point sepa-
rated on a 150 x 0.075 mm nanoC18 HPLC column prior
to analysis on an Orbitrap-velos mass spectrometry system
as described previously [47]. LC-MS data was searched
against Uniprot database using Mascot 2.4 and interro-
gated using Proteome Discoverer 1.4. Quantification of
the identified phosphopeptides by generating extracted
ion chromatograms was performed using Xcalibur 2.2
software.
Nuclear lysates were isolated as described above, and
aliquots alkylated prior to separation by SDS-PAGE
and either coomassie staining or western blot (with
phospho specific antibodies to CRMP2 to identify
CRMP2A). The protein band equivalent to the molecu-
lar mass of CRMP2A was excised and the destained
protein band digested with 20 μl 12.5 μg/ml trypsin
(Roche, Sequencing Grade) in 20 mM ammonium
bicarbonate overnight at 30 °C. To each digest 20 μl of
100 % acetonitrile was added and incubated for 15 min
then the supernatant removed. 30 μl of 5 % formic acid
was then added to each gel piece and incubated for
15 min prior to the addition of an equal volume of
100 % acetonitrile (2.5 % formic acid final concentra-
tion). This extract was then removed and pooled with
the original extract from the digest. A further 10 μl of
100 % acetonitrile was added to each and incubated for
10 min prior to pooling with the previous 2 extracts.
The pooled extracts were then dried down, resus-
pended in 10 μl of 5 % formic acid then diluted to 1 %
prior to injection. 15 μl of sample from each time point
was separated on a PepMap RSLC C18, 2 μM column
(75 μM × 50 cm nanoViper) (Thermo Scientific) con-
nected to an Ultimate3000 RSLCnano System (Thermo
Scientific) coupled to a LTQ Orbitrap Velos Pro (Thermo
Scientific) via a EasySpray source Thermo Scientific). Orbi-
trap Velos Pro .RAW data files analysed with Proteome
Discoverer (Ver. 1.4.1) using Mascot (Ver. 2.4.1) as the
search engine against the IPI Human Database and
sequence of CRMP2A.
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Statistical analysis
All statistical analysis was performed using Prism 6.0
software (GraphPad software, CA, USA). Calculation of
the mean was used to determine central tendency and
standard error of the mean was calculated to quantify
the precision of the mean. For comparison of substrate
phosphorylation following transfection of p35/CDK5
and p25/CDK5 with untransfected control, statistical
analysis was performed by one-way analysis of variance
(ANOVA) with Tukey’s post hoc test as comparisons be-
tween each group. For comparisons between squamous
cell carcinoma and adenocarcinoma, a student’s t-test was
performed. A p value of <0.05 was considered significant
and p values are expressed in relevant figures using aster-




As an initial assessment of the potential roles of CDK5
in human cancers, we interrogated Oncomine (https://
www.oncomine.org/) and COSMIC (https://www.san-
ger.ac.uk/research/projects/cancergenome/) to search
for evidence of differential expression or mutation of
CDK5 and its two partners CDK5R1 (p35) and CDK5R2
(p39) in a range of cancer types. In the Oncomine data-
base of gene expression profiles, CDK5 mRNA levels
are lower in brain cancers compared to normal brain tis-
sues and higher in a variety of other cancer types, notably
breast, lung and lymphoma compared to the correspond-
ing normal tissues. CDK5R1 shows a similar pattern in
these cancers, whereas CDK5R2 is not commonly altered
(Table 1). In the COSMIC database, mutations or copy
number changes in any of these genes occurs very rarely
(33/15583 for CDK5; 42/15259 for CDK5R1 and 30/15259
mutations for CDK5R2; all <0.3 %; accessed 3rd March,
2015). This suggests that genetic alteration and/or gene
expression changes in CDK5 or its cofactors are not a
common cause of, or contributor to, oncogenesis. How-
ever this does not rule out disease-related post-
translational alteration in CDK5 activity, and thus we
decided to investigate CDK5 substrate measurements as
a means to assess CDK5 activity in human tumours.
CDK5 substrates as biomarkers
Previous work demonstrated that CDK5 has an abso-
lute requirement for a Proline (Pro) residue immedi-
ately C-terminal (+1) to the phosphorylation site of its
substrates, while the presence of a C-terminal Arg/Lys
residue (+3 > +4 > +2) enhances phosphorylation of
substrates even further [48]. Meanwhile investigation of
the sequence of CDK5 substrates proposed in the litera-
ture indicates that although all contain the Pro at +1
the presence/position of a C-terminal Lys/Arg residue
is quite variable (Table 2). This questions the confidence
in Arg/Lys residues to the prediction of substrate recogni-
tion for CDK5, or the accuracy of some of the proposed
substrates in the literature. Therefore using peptide assays
we re-investigated the importance of Arg/Lys residues
around the substrate phosphorylation site for both p35/
CDK5 and p25/CDK5. Firstly we confirm that the presence
of a Arg/Lys residue at +3 and/or +4 is a major enhancer
of substrate recognition for both CDK5 complexes, at least
in vitro (Fig. 1a). CDK5 isoforms phosphorylated a peptide
containing the sequence TPKRR at a much higher rate
than one with the sequence TPKAA (where the phosphor-
ylated residue is underlined, Fig. 1a). Indeed the latter
peptide is an extremely poor substrate for both p35/CDK5
and p25/CDK5 (Vmax/Km <0.05, compared to 0.6-0.8
for TPKKR), suggesting for the first time that the pres-
ence of a single Arg/Lys residue at +2 is relatively poor
at conferring CDK5 recognition (Fig. 1a). This questions
the validity of a number of the proposed CDK5 substrates
in the literature (Table 2). Indeed one can find examples
of 4 different classes of CDK5 substrate, 1) Arg/Lys resi-
dues both N- and C-terminal to the phosphorylated resi-
due (±5), 2) Arg/Lys residues solely C-terminal, 3) Arg/
Lys residues solely N-terminal and 4) no Arg/Lys residues
Table 1 Summary of expression changes of CDK5, CDK5R1 and
CDK5R2 in human cancers
Red boxes indicate the number of studies showing increased mRNA levels and
blue reduced mRNA levels. Shading reflects the extent of altered expression
compared to the corresponding normal tissues
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either side of target residue. We synthesised 4 peptides
representing each class of substrate sequence that re-
semble proposed CDK5 substrates, and incubated them
with each CDK5 complex (Fig. 1b). In this case Class 1
peptides (with Arg/Lys residues both N- and C-
terminal to the phosphorylated residue) were much
better substrates than peptides based on other sub-
strate classes (Fig. 1b). Surprisingly the class 2 pep-
tide, with two C-terminal Arg/Lys residues (at +3
and +5), but none N-terminal, was a relatively poor sub-
strate in comparison to the class 1 peptide (that contained
three C-terminal (+2, +3 and +5) and also one Arg/Lys
residue N-terminal (at −1)). Peptides lacking a C-terminal
Arg/Lys residue (class 3 and 4) were not phosphorylated
by either CDK5 complex, even when N-terminal Arg/Lys
residues were present (Fig. 1b). This data suggests that
multiple C-terminal Arg/Lys residues greatly enhance
phosphorylation by CDK5 with those at +3/4 being crucial
for recognition by CDK5.
We extended this comparison to peptides where the
number and position of the Arg/Lys residues varied
(Fig. 1c). The class 1 peptide (Lys/Arg at −1, +2, +3,
Table 2 Comparison of primary structures of proposed CDK5 substrates
Substrate Phosphorylated sequence Proposed effect of phosphorylation
CLASS 1 (Lys/Arg residues N- and C-terminal)
CRMP2 PASSAKTSPAKQQ (S522) Axon Growth and development
CRMP4 PAGSARGSPTRP (S522) Myelin dependent axon outgrowth
Synaptojanin EAPKSPGTTRKD (S1144) Inhibits interaction with endophilin 1
Tau TPPKSPSSAKS (S235/AT180) Makes tau a better substrate for GSK3
Tyr Hydroxylase-1 YTPTPRSPRFIGRR (S31) Makes protein more stable
ATM CLCIHTKHTPNKIAS (mouse S793) Activation of ATM- apoptosis
Bcl-2 EMAARTSPLRPLV (mouse S80) Induces neuronal survival
Cdh-1 SQKLLRSPRKPTRK (mouse S163) Stabilises cyclin B1
mSDS3 (HDAC) NKLKSPKRPASPSS (mouse S224) Promotes dimerisation and activation
PIK-A RGKLSPRKGKSKTL (mouse S279) Stimulates PI 3-kinase/Akt pathway
Neurabin I GKGGHSSPQRRMKPKEF (S95) Regulates binding to F-actin
CLASS 2 (Lys/Arg residues C-terminal only)
DARPP32/PPP1R1B PCAYTPPSLK (T75) Phospho-DARPP32 inhibits PKA
Inhibitor-1 MEQDNSPRKIQFTVP (S6) Regulates activity toward PP1
Dynamin I SPTSSPTPQRRAPA (T778) Regulates endocytosis
Inhibitor-1 TLAMSPRQRKKMTRITP (S66) Regulates activity toward PP1
SPAR LGAATSSPRSGPGKE (S1328) Regulates synaptic plasticity
Cdh-1 ANSPVSSPSKHGDR (mouse S40) Stabilises cyclin B1
Mef2A SEPISPPRDRMTP (mouse 406) Regulates apoptosis
Mek1 GDAAETPPRPRTP (mouse T283) Inhibits MEK signalling
p53 CTSASPPQKKKPL (mouse S314) Regulates apoptosis of PC12 cells
PLD2 FAVTHSPAREAA (mouse S134) Activation (part of EGF action)
STAT3 IDLPMSPRTLDS (mouse S727) Upregulated transcriptional activity
Stathmin (Leukemia-associated phosphoprotein p18) VPDFPLSPPKKKD (mouse S41) Stabilises protein
Talin EDSVSPKKSTVLQ (mouse S425) Regulates binding to smurf1/cell migration
CLASS 3 (Lys/Arg residues N-terminal only)
Doublecortin STPKSKQSPISTPT (mouse S332) Unclear
CLASS 4 (No Lys/Arg residues)
FAK EGFYPSPQHMVQT (mouse S766) Critical for neuronal migration
p53 PEDILPSPHCMDDL (mouse S33) Regulates apoptosis of PC12 cells
PSD95 LPNQANSPPVIV (S35) Regulates structure of synapse
Primary sequence surrounding proposed CDK5 target residues; substrates are classified by presence of Arg/Lys residues (underlined) within 5 amino acids N-terminal or
C-terminal to the phosphorylated residue which is always N-terminal to a proline
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and +5, peptide 1.0) was phosphorylated at twice the rate
to one where the +2 Arg/Lys residue was replaced by Ala
(peptide 1.1), or the −1 Arg/Lys residue was replace by Val
(peptide 1.2). Peptide 1.3 was identical to peptides 1.0 and
1.1 except the +2 residue was a Pro (a modification which
may have rendered peptide 2 in Fig. 1b a poor substrate).
This single amino acid change reduces the rate of phos-
phorylation by >90 % compared to peptide 1.0 and 1.1
(Fig. 1c). Interestingly the substrates Mef2A, MEK1,
stathmin, DARP32, PSD95 and p53 (at Ser314) have a Pro
at this position relative to their proposed phosphorylation
site, implying that these proteins should be relatively poor
CDK5 substrates (Table 2). Indeed we confirmed that
Mef2A and p53 are very poor substrates for CDK5, in
vitro at least (Table 3). Interestingly none of the class 1
substrates listed in Table 2 have a Pro at position +2.
This dramatic negative effect of a Pro substitution at +2
prompted us to investigate whether the presence of three
Pro residues in close proximity to the phosphorylation site
in peptide 1.3 worsened the rate of phosphorylation rather
than the specific position. We replaced the Pro at −2 in
peptide 1.3 with Val to generate peptide 1.4 in Fig. 1c.
However this modification did not restore phosphorylation
of the peptide by CDK5 (peptide 1.0-Pro vs 1.4-Lys), indi-
cating the Pro at +2 is a novel inhibitory structural feature
in substrate recognition for CDK5.
A B
C D
Fig. 1 In vitro analysis of primary sequence determinants for p35/CDK5 and p25/CDK5. a The contribution of C-terminal Arg/Lys residues to recognition
and phosphorylation by each CDK5 complex was assessed by incubating the peptides at the indicated concentrations with 2 m units of each CDK5
complex for 20 mins and measuring phosphate transferred to each peptide. b Each CDK5 complex was incubated for 20 mins with 100 μM of
the indicated peptides representing the primary sequence of the 4 classes of CDK5 substrates. The phosphorylated residue is underlined. c To
assess the contribution of specific residues ±2 positions from the target residue a further 4 peptides (at 100 μM) were incubated with 2mUnits
of each CDK5 complex for 30 mins. The residue changed from the parent sequence (peptide 1.0) is in italics in each case. *indicates p < 0.05
compared to peptide 1.0. d The rate of phosphorylation of the indicated peptides by several members of the CMGC family of kinases was compared by
incubating each peptide (at 50 μM) with 2 m units (as determined against the generic substrate MBP) of each kinase for 30 mins and phosphate transfer
measured. In all figures the data is presented as the average of at least two different experiments performed in duplicate ± the SEM, and is given as total
picomoles transferred during the assay (a) or pmoles transferred/min (b-d)
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Finally we incubated these peptides with several other
members of the CMGC protein kinase family in order to
investigate the selectivity of the Arg/Lys and proline resi-
due features identified for CDK5 (Fig. 1d). Peptide 1.0 is
highly selective for CDK5, with only PICTAIRE showing
any ability to phosphorylate this peptide to any significant
level (<80 % that of a matched amount of MBP kinase ac-
tivity of CDK5). Similarly, CDK5 is the most effective kin-
ase at phosphorylating peptides 1.1 and 1.2 (Fig. 1d).
However, PICTAIRE phosphorylates peptide 1.3 (with
Pro at +2) to a greater extent than CDK5 (or any other
CMGC kinase tested, Fig. 1d), suggesting that substrates
with a S/TPP sequence are likely to be better PICTAIRE
targets than CDK5 (such as Mef2A and p53).
In summary this data identifies four novel aspects of
CDK5 substrate recognition, firstly that N-terminal
Arg/Lys residues can enhance phosphorylation by CDK5,
secondly that multiple C-terminal Arg/Lys residues im-
prove the phosphorylation rate, thirdly that a Pro at +2
antagonises phosphorylation by CDK5 and finally that a
Pro at −2 enhances recognition by CDK5 compared to an
Arg/Lys residue. There were no differences in the rates of
peptide phosphorylation between each CDK5 complex in
vitro and we propose that peptide 1.0 is a relatively
selective substrate to distinguish between CDK5 and other
members of the CMGC kinase family.
These primary sequence determinants focused our
attention on class 1 substrates for assessing CDK5 activ-
ity in cells and tissues.
CDK5 substrate phosphorylation in vitro
We compared the rate of phosphorylation of collapsin
response mediator proteins (CRMP) by each CDK5
complex (Fig. 2a). Three members of the CRMP family
are class 1 CDK5 substrates [18]. Both CDK5 complexes
phosphorylate CRMP1, CRMP2 and CRMP4, and this is
reduced by >75 % in the Ser522Ala mutant of each
CRMP (Fig. 2a), indicating that Ser522 is the major site
for phosphorylation by CDK5 in this substrate. In
addition, each CDK5 complex phosphorylates tau pro-
tein in vitro (Fig. 2b), and this activity is completely
Table 3 Comparison of phosphorylation rates of proposed
CDK5 substrates
p35/Cdk5 p25/Cdk5
Vmax Km Vmax/Km Vmax Km Vmax/Km
CRMP4 0.665 0.401 1.660 0.155 0.252 0.6151
CRMP1 0.735 1.260 0.594 0.191 1.458 0.131
CRMP2 0.722 1.650 0.438 0.179 1.660 0.108
Tau 0.630 1.890 0.3347 0.261 1.419 0.186
Dynamin 1 0.309 2.780 0.111 0.187 2.040 0.092
p53 ND ND ND ND ND ND
PPARγ ND ND ND ND ND ND
Mef2a ND ND ND ND ND ND
Phosphorylation kinetic parameters were established during initial rate conditions
by incubating equal amounts of p35/Cdk5 and p25/Cdk5 with varying
concentrations of the indicated substrates and Mg [γ-32P] ATP for 10 min at 30 °C.
Vmax and Km values were calculated using the Lineweaver-Burk equation. Vmax
values are in pmol/min and Km are in μM. Values are representative of at least two
independent experiments performed in duplicate. ND; not determinable, these
substrates were not phosphorylated to a significant level under these conditions
A B
Fig. 2 Analysis of CRMP and tau phosphorylation by CDK5 in vitro. Recombinant protein substrates (0.5 μM final concentration) were incubated with
2mUnits of each CDK5 complex and MgCl2 and [γ-32P] ATP (approx 0.5x106 CPM/nmole) for 30 mins. Reactions were terminated by the addition of
SDS-PAGE loading buffer and heating to 70 °C. Aliquots were subjected to SDS-PAGE, stained with Coomassie Brilliant Blue (CBR-250), the gels were
dried and radiolabeled bands visualized by autoradiography. a Comparison of CRMP-1, −2 and −4 (wild-type and Ser522Ala mutants) phosphorylation by
each CDK5 complex. b GST-tau (0.5 μM final concentration) was incubated with 2mUnits of each CDK5 complex for 30 min, with or without a 30 min
pre-incubation with the Cdk inhibitors roscovitine (10 μM) or purvalanol A (10 μM). Data is representative of at least three different experiments
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blocked by the inclusion of either of two CDK inhibi-
tors. Mass Fingerprinting found the major purvalanol
A- and roscovitine-sensitive phosphorylation site on tau
is Ser-235 (a class 1 site), with minor phosphorylation
of Ser202/Thr205 (Additional file 2: Figure S1a). This
was subsequently confirmed by immunoblot using site-
specific antibodies (Additional file 2: Figure S1b). The high
preference for Ser235 was unexpected as previous studies
had indicated that CDK5 phosphorylates numerous resi-
dues on tau [49]. For example, Ser231 was reported as a
CDK5 target and was not found in our studies, yet Ser231
was phosphorylated by GSK3 after tau phosphorylation at
Ser235 by CDK5 (Additional file 2: Figure S1b). Therefore
phosphorylation at Ser235 turns tau into a substrate for
GSK3 at Ser231 making this site look like a CDK5 site in
cells. Importantly >80 % of the phosphate incorporation
(at least after 60 min incubation with CDK5 in vitro) is
accounted for by Ser235/Ser202/Thr205 phosphorylation.
This does not rule out additional sites on tau are phos-
phorylated in longer incubations, or in vivo. However we
focused subsequent studies on tau phosphorylation by
CDK5 only at these three residues. We investigated several
additional proposed CDK5 substrates (Table 3), however
in comparison to CRMPs and tau these were relatively
poorly phosphorylated in vitro, making confirmation of
phosphorylation site difficult. Hence we focused on estab-
lishing whether these specific sites identified on CRMP or
Tau could be developed as markers of CDK5 activity in
cells or tissues.
CDK5 substrate phosphorylation in cells
Human CRMP2 or CRMP4 was co-expressed with or
without the CDK5 catalytic subunit and either p25 or p35
in HeLa cells (Additional file 2: Figure S2). Cells were lysed
and protein lysates probed for the expression and phos-
phorylation of CRMP2 (Additional file 2: Figure S2a
and b) or CRMP4 (Additional file 2: Figure S2c and d).
Overexpression of either CDK5 complex enhances
CRMP2 phosphorylation at Ser522, but in contrast
Ser522 phosphorylation of CRMP4 is not influenced by
overexpression of either CDK5 complex. This implies
CRMP4 is not a CDK5 substrate when expressed in cells
or that the Ser522 site on ectopic CRMP4 becomes rapidly
and fully phosphorylated by endogenous CDK5. The in-
duction of Ser522 phosphorylation of CRMP2 by p25/
CDK5 was greater than that for p35/CDK5 however the
expression of p25 was consistently greater than p35
(Additional file 2: Figure S2a and c).
When either CDK5 complex is co-expressed with tau in
HeLa cells (Additional file 2: Figure S3) there is a signifi-
cant increase in phosphorylation of all of the 3 sites that
we identified in the in vitro analysis above. Interestingly
these sites are poorly phosphorylated in the absence of
CDK5 co-expression while the effect of p25/CDK5 was
similar to that of p35/CDK5 implying no major difference
in targeting by alteration of the p35-p25 ratio in cells.
These data support the hypothesis that an increase in
CDK5 expression and/or activity associated with disease
would alter the phosphorylation of CRMP2 (at Ser522)
and tau (at Ser235 and Ser202/Thr205), and thus these
substrates are potential biomarkers of aberrant CDK5
activity.
Next we used immunofluorescence to investigate
whether our phosphospecific antibodies could selectively
detect phosphorylation of endogenous CRMP or tau in
primary cells (Fig. 3a). We incubated primary neurons
with or without purvalanol A (CDK inhibitor) and then
fixed and stained the isolated cells for substrate phosphor-
ylation. CDK inhibition reduces CRMP2 phosphorylation
at Ser522 but does not alter CRMP4 phosphorylation.
Taken together with the CRMP and CDK5 co-expression
data (Additional file 2: Figure S3) this indicates that
Ser522 of CRMP2, but not CRMP4, is a physiological tar-
get for CDK5. This is in agreement with previous work in
CDK5 null tissue where CRMP2 phosphorylation is absent
yet CRMP4 phosphorylation at Ser522 persists [20].
Tau phosphorylation at Thr205 but not Ser202 is
reduced by CDK inhibition (Fig. 3a). However the signal
to noise ratio for the phospho-Ser235 antibody is very
weak which makes assessing changes in phosphorylation
of this site difficult even in cells with high levels of tau.
This questions whether tau phosphorylation is a useful
biomarker of CDK5 activity, however we cannot rule out
that Ser235 phosphorylation could be increased in a disease
specific manner, only becoming significant when CDK5
activity increased above levels detected in healthy tissue.
Next we investigated immunohistochemical staining of
phospho-CRMP2 and phospho-tau after the primary
neurons were embedded in paraffin to accurately mimic
the fixation and processing of human clinical tissues
used in diagnostic histopathology (Fig. 3b). The intensity
of staining and the number of cells stained with the anti-
body to phospho-Ser522 of CRMP2 is reduced by CDK
inhibition (by both purvalanol A and roscovitine). In
contrast tau phosphorylation at Ser235 or Thr205 is not
significantly affected by the inhibitor treatment (Fig. 3b).
Therefore our in vitro and cell based studies suggest
that of all of the potential substrates examined CRMP2
phosphorylation at Ser522 is most worthy for investiga-
tion as a surrogate marker for altered CDK5 activity in
tumour tissue.
CRMP2 phosphorylation in tumours
Previous work had suggested that altered expression/phos-
phorylation of specific CRMP isoforms was associated with
lung and breast cancer [50–54]. Therefore we initially
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investigated biopsies from 21 different non-small cell lung
cancer (NSCLC) patients for pSer522 CRMP2 staining
(Fig. 4). The staining was graded by two independent pa-
thologists using a semi-quantitative scale from 1–3, with 1
representing low intensity staining, 2 moderate staining and
3 high level staining. Staining for pSer522 is strong in the
nucleus of tumour cells but is absent from the surrounding
non-neoplastic epithelium (Fig. 4a and b). Interestingly this
initial investigation suggested that immunopositive staining
is more a feature of squamous cell carcinoma (8/11 with a
score of 2 or 3, average score = 1.91) than adenocarcinoma
















































Fig. 3 Imaging of CDK5 substrate phosphorylaiton in primary cells. Rat primary cortical neurons were cultured for 6 days in vitro. a Cells were incubated
with 10 μM purvalanol A or vehicle for 3 h prior to fixation, permeabolisation and staining with the indicated antibodies. Phosphospecific antibodies were
detected by Cy-3 bound 2ry antibodies (red) and nuclei were counter-stained with the DNA-binding dye DAPI (blue). Scale bar = 60 μm. b The
primary neuronal cultures were incubated with either 10 μM purvalanol A, roscovitine or vehicle for 3 h prior to fixation in formaldehyde and
embedding in paraffin. Sections were taken from each paraffin block and incubated with the phospho-antibodies as indicated, then biotinylated secondary
antibody followed by streptavidin complexed with biotinylated peroxidases which were visualized using DAB staining. Cell nuclei were counterstained with
hematoxylin and mounted in DPX. Scale bar= 100 μm. Images are representative of sets from at least three different neuron preparations
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Fig. 4 CDK5 substrate phosphorylation in human tissue. a Nineteen lung tumour biopsies were immunostained with the pCRMP2 S522 antibody and
developed with DAB. Tumour sections were designated squamous (11), adenocarcinoma (4) or other (4) and graded using a semi-quantitative scale from
0–3, with 0 representing no staining, 1 representing light brown staining, 2 representing moderate brown staining and 3 representing dark
brown staining. Representative images for each grade are provided. Clear nuclear (n) or cytoplasmic (c) staining is indicated, and slides where
the staining was specific to tumour tissue rather than healthy tissue are indicted by (t). b A second independent cohort of adenocarcinoma (ADC) and
squamous cell carcinoma (SCC) sections (9 of each type) were immunostained with the pCRMP2 Ser522 antibody and scored as in A. Representative
histology for each is provided in upper panel (Scale bar= 50 μm), while the individual and average scores for pCRMP2 Ser522 staining is given below
as mean ± S.E.M. t-test, *P < 0.05, **P < 0.01, ***P < 0.001
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investigate this in more detail an additional 18 lung tumour
samples were obtained containing roughly equal numbers
of both tumour types in order to compare histologically
graded staining between adenocarcinoma and squamous
cell carcinoma. In addition, a squamous carcinoma from
skin was included as this is histologically different from
squamous carcinoma sourced from other areas of the body.
The staining was graded as described above. Consistent
with the preliminary observation, Ser522 phosphorylated
CRMP2 is predominantly localised in the nuclei of cancer
cells and absent from healthy tissue, confirming the associ-
ation of this phosphorylation with tumourigenesis and the
unusual localisation of the CRMP2 (Fig. 4c). CRMP2 phos-
phorylation at Ser522 has a higher intensity in squamous
cell carcinoma compared to adenocarcinoma immuno-
staining. No phospho-Ser522 staining is observed in skin
squamous carcinoma (data not shown), suggesting both
selectivity in tumour reactivity, and a potential clinical
utility for the pSer522 antibody to identify lung metastasis.
The oncomine data on gene expression levels indicated
that CDK5 itself is not differentially expressed in lung can-
cer subtypes (Table 1), but CDK5R1 mRNA levels are
higher in lung squamous cancers than adenocarcinomas.
The lack of common CDK5 mutations associated with
oncogenesis is perhaps not that surprising as there are no
known point mutations that promote constitutive activa-
tion of CDK5. It is not even clear if enhanced CDK5 ex-
pression would induce greater cellular CDK5 activity
without a simultaneous upregulation of p35 or p39. Up-
regulation of CDK5 activity could occur due to changes in
the expression/regulation of one or other of its regulatory
subunits, but again it is not clear whether this would
enhance cellular CDK5 activity without simultaneous in-
crease in the catalytic subunit of CDK5. In addition, there
are no reported point mutants in CDK5R1 or CDK5R2
that result in significant increases in CDK5 activity. Rather
the ratio of p35 to its cleavage product p25 is proposed to
alter subcellular location and potentially substrate selec-
tion. This makes monitoring associations between altered
CDK5 activity and oncogenesis difficult without robust
markers of intracellular CDK5 activity. Interestingly, the
phosphorylation of the CDK5 substrate CRMP2 is
altered in lung [52, 54] and breast [53] carcinoma, how-
ever those studies implied that it was changes in
Thr509/Thr514 phosphorylation of CRMP2 that associ-
ated with carcinoma. These are not CDK5 phosphoryl-
ation sites. However we have previously established
that CRMP2 phosphorylation at Ser522 by CDK5 is a
prerequisite for the subsequent sequential phosphoryl-
ation of CRMP2 at Ser518, Thr514 and finally Thr509
by GSK3 [20]. Thus enhanced Ser522 phosphorylation
is likely to be required for induction of, and may be suf-
ficient to induce, the phosphorylation of CRMP2 at
Thr509/514. Therefore our study links, for the first
time, CRMP2 phosphorylation at Ser522, the CDK5 tar-
get site, to carcinoma. This is of particular mechanistic
importance since the reported increase in Thr509/514
phosphorylation implicates increased GSK3 as the poten-
tial driver leading to enhanced phosphorylation of CRMP2
in carcinoma, however our data identifying enhanced
Ser522 phosphorylation indicates that this is not necessar-
ily true. Rather, increased CDK5 would also indirectly lead
to enhanced phosphorylation of Th509/514 of CRMP2
subsequent to the increase in Ser522 phosphorylation. It is
quite possible that there is a synergistic effect of a com-
bined increase in GSK3 and CDK5 activity. This has major
implications for understanding the underlying biochemis-
try of tumours with altered CRMP2 phosphorylation and
the potential development of interventions.
As changes in Thr509/514 phosphorylation of CRMP2
had been reported in more than one carcinoma we
investigated the tumour selectivity of Ser522 immuno-
staining further in tissue microarrays (TMA), covering an
additional eight human tumour types (Tables 4). There is
only a single positively stained core in the control TMAs,
so control tissue is deemed negative for pCRMP2 Ser522
staining. Likewise, ovarian, renal, prostate and colorectal
cancers are almost completely negative for pCRMP2
Ser522 staining, with less than 1.7 % expressing immuno-
positive staining. Positive staining is observed in the breast
TMA however this constitutes only 8 % (4/48) of patient
samples and these all have a relatively low quick score of
3. Previously Shimada and colleagues reported increased
phosphorylation of Thr509 of CRMP2 in the nuclei of
Table 4 Quick Score = Category A + Category B (possible 0-9),
number of cases with each score given in columns for each
cancer type
Quick Score (A + B)
1 2 3 4 5 6 7 8 9 Cases
Controls 0 1 0 0 0 0 0 0 0 14
Ovarian 0 0 0 1 0 0 0 0 0 79
Kidney 0 0 1 2 0 0 0 0 0 181
Prostate 0 1 1 0 0 0 0 0 0 25
Breast 0 0 4 0 0 0 0 0 0 48
Colorectal Adenoma 0 0 0 2 0 0 0 0 0 127
Follicular Lymphoma 0 2 1 1 0 0 0 0 0 46
Diffuse Large B-Cell
Lymphoma (DLBCL)
0 9 10 13 5 0 0 0 0 77
Sections were stained using the anti-pCRMP2 Ser522 and visualised using DAB
chromogen. The proportion of malignant cells staining positively throughout
the section (termed Category A) was assigned scores from 1–6 (1 = >0 - 5 %;
2 = 6 - 20 %; 3 = 21 - 40 %; 4 = 41 - 60 %; 5 = 61 - 80 %; 6 = 81 -100 %); the
average intensity of staining in malignant cells (termed Category B) was scored
as 0, 1, 2, or 3, corresponding to the presence of negative, weak, moderate,
and strong brown staining, respectively. Category A and Category B values were
added together to produce a quick score (range from 0, negative, to 9, strong
and complete). The table provides the number of cases of each tumour type with
each quick score. A tumour was considered negative when all sample cores were
negative, whereas > 2 positive cores was considered a positive result
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breast carcinoma and that this increased in proportion to
the histological grade and triple-negative subtype [53].
The relatively low numbers of breast samples on our
TMA prevents a similar investigation in our study. A simi-
lar number of sample cores taken from follicular lymph-
omas are positive for pCRMP2 Ser522 staining (10 %).
Interestingly, a much higher proportion of immunoposi-
tive cells are observed in sample cores from diffuse large
B-cell lymphoma (DLBCL) with almost half (48.1 %) of pa-
tient cases scoring positive and half of those with a quick
score >3 (Tables 4). This suggests that pCRMP2 Ser522 is
present in more than just lung carcinoma, and is particu-
larly abundant in DLBCL. CRMP2 has been proposed to
contribute to T-lymphocyte polarisation and migration
[55], and increased expression of CRMP2 in peripheral T
lymphocytes is associated with their recruitment to the
brain following virus-induced neuroinflammation [56].
However this is the first indication that changes in CRMP2
phosphorylation, and by implication CDK5 regulation of
CRMP2, are associated with B-lymphocyte biology, in
health or disease.
Nuclear staining of CRMP2 is unusual
The immunostaining of the nucleus of tumour cells with
the anti-pCRMP2 Ser522 antibody is an unexpected re-
sult as there is very limited evidence that CRMP2 enters
the nucleus of cells (most work has been done in neu-
rons). As far as we are aware there is currently only one
report proposing that phosphorylated CRMP2 is in the
nucleus, with phospho-509/514 of CRMP2 being de-
tected by immunofluorescence in the nucleus of breast
cancer cells [53].
To confirm the nuclear CRMP2 localisation using bio-
chemical techniques we selected three human lung cancer
cell lines representing different subtypes of NSCLC. The
EBC-1 cell line is derived from human lung squamous cell
carcinoma [57], the A549 cell line was initiated through
explant culture of lung carcinomatous tissue and is used
as a cell-based model of adenocarcinoma [58], and finally
the NCI-H460 cell line which is often used as a model
of large cell carcinoma [59]. We performed subcellular
fractionation of these lines along with the human neuro-
blastoma cell line, SHSY5Y, as a positive control for
Fig. 5 Sub-cellular localization of phosphorylated CRMP2. Subcellular fractionation of three cancer cell lines (A549, EBC-1 and H460), and a human
neuroblastoma SHSY5Y cell line (positive control for CRMP2 expression) was performed prior to Western blot analysis with the indicated antibodies.
GAPDH and histone H4 were used as markers for the successful fractionation of cytoplasm and chromatin-bound nuclear fraction, respectively. Western
blots shown are representative of three independent experiments
Grant et al. BMC Cancer  (2015) 15:885 Page 13 of 16
CRMP2 expression (Fig. 5). The resultant nuclear, mem-
brane and cytoplasmic protein fractions were immuno-
blotted using total CRMP2 and pCRMP2 Ser522
antibodies. Fractionation efficiency was assessed by immu-
noblot using an antibody to anti-GAPDH (cytoplasm) and
anti-histone H4 (nuclear (chromatin-bound)).
The most abundant form of CRMP2 protein (62 kDa) is
found only in the cytoplasmic fraction for all cell lines
(Fig. 5). However, a form of CRMP2 with greater mass is
detected in the soluble nuclear fraction, and this corre-
sponded to the molecular mass of a less abundant form of
CRMP2, termed CRMP2A (75 kDa) that has an N-terminal
extension due to alternative splicing [60]. The CRMP2A
isoform is thought to have a divergent function to the more
common CRMP2 isoform, and was previously reported to
be isolated to axons in neurons [60]. We detect the 75 kDa
form using both the anti-pCRMP2 Ser522 and total
CRMP2 antibody giving greater confidence that this is truly
the CRMP2A isoform and implying that phospho-CRMP2
does exist in the nucleus of cancer cells (it was also de-
tected in the human neuroblastoma SHSY5Y). To obtain
additional evidence supporting nuclear CRMP2A localisa-
tion, peptide identification by Mass Spectrometry (1D
nLC-MS/MS) of the fractionated nuclear protein lysate was
performed, as this technique is independent of antibody
specificity. We positively identify four peptides that corres-
pond to human CRMP2 sequence, three of which are com-
mon to both CRMP2A and CRMP2B (IAVGSDADLVIW
DPDSVK, DIGAIAQVHAENGDIIAEEQQR, NLHQGFSL
SGAQIDDNIPR), but one that is only found in the N-
terminal extension region of CRMP2A (IVNDDQSFYAD
IYMEDGLIK). This provides compelling evidence that
CRMP2A is indeed present within the nucleus. Thus
alternative splicing of CRMP2 regulates its nuclear local-
isation and it is specifically CRMP2A phosphorylation that
is associated with lung, breast and lymphocyte tumour
staining. This may provide the basis for development of a
novel and highly selective intervention.
Conclusions
We demonstrate that an antibody that selectively detects
a validated CDK5 phosphorylation site on the substrate
CRMP2 robustly stains NSCLC, B-cell lymphoma and to
a lesser extent breast carcinoma. Furthermore we show
for the first time that it is a specific splice variant of
CRMP2 that localises to the nucleus of cancer cells. We
propose that CDK5 regulation of CRMP2A could con-
tribute to cancer initiation and progression, and this is
supported by recent evidence implicating CDK5 activity
in taxol-induced cancer metastasis [61]. Phosphorylation
of CRMP2 by CDK5 is associated with altered function
in neurons [62], however the role of phosphorylation of
CRMPs by CDK5 in cancer has not yet been studied.
We demonstrate that there are no inherent differences in
the activity of p35/CDK5 and p25/CDK5 towards any sub-
strates tested. Whilst the CRMP4 isoform is proposed as a
metastasis suppressor in prostate cancer the role of
CRMP4 phosphorylation in this action has not been inves-
tigated [63]. However our data questions whether CRMP4
is a substrate for CDK5 in healthy cells, or when we in-
crease CDK5 expression. Therefore we propose the CDK5
upregulation would influence CRMP2 but not CRMP4,
and furthermore propose that it is the CRMP2A isoform
that is a novel oncogenic target for CDK5. This work pro-
vides the opportunity for development of additional tools
aimed at this CDK5-CRMP2A axis to combat cancer initi-
ation, progression and metastasis.
Additional files
Additional file 1: Table S1. Peptide Sequences used in Fig. 1. (DOC 30 kb)
Additional file 2: Figure S1. A- GST-Tau was incubated with p35/CDK5
or p25/CDK5 and [γ-32P]-ATP for the times indicated, then subjected to
SDS-PAGE prior to autoradiography (upper section). Tau bands were
digested with Lys-C and phosphopeptides isolated and identified as
described in Methods. A major phosphopeptide eluted with mass/charge
ratio of 802.4331 corresponding to the peptide containing Ser235 (lower
section), and a second doubly phosphorylated peptide corresponding to
a peptide including Ser202 and Thr205 was also identified but at much
lower abundance. The same result was obtained from two different
phosphorylation reactions. B- GST-tau was phosphorylated as above but
using non-radioactive ATP. Proteins were transferred to nitrocellulose
after SDS-PAGE and probed with the indicated antibodies. Data is
representative of two experiments. Figure S2. Co-expression of CDK5
complexes with CRMP2 and CRMP4. Hela cells were co-transfected with
equal amounts of expression constructs for CDK5 catalytic subunit, p35
or p25 and FLAG-tagged CRMP2 (A and B) or CRMP4 (C and D) as
indicated. Cells were lysed and protein expression and phosphorylation
assessed by Western blot analysis (A and C). Quantification was performed
on a Licor Odyssey (B and D) with data shown as mean ± S.E.M of three
experiments in duplicate. t-test, *P < 0.05, **P < 0.01, ***P < 0.001. Figure S3.
Co-expression of CDK5 complexes with tau. Hela cells were co-transfected
with equal amounts of expression constructs for CDK5 catalytic subunit, p35
or p25 and tau. Cells were lysed and protein expression and phosphorylation
assessed by (A) Western blot analysis. (B-D) Quantification was performed on
a Licor Odyssey and the ratio between phospho-tau: total tau calculated for
each phospho-tau antibody. Data shown as mean ± S.E.M. for three
experiments performed in duplicate. t-test, *P< 0.05, **P < 0.01, ***P < 0.001.
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